New Haven, Conn.-based Yale School of Medicine and Atlanta-based Emory University researchers found a weak association between FDA drug proxies and disease outcomes — putting into question the effectiveness of using proxies in the approval process.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
